Poster note: Target discovery program in systemic sclerosis

Posted: 14 September 2016 | | No comments yet

Novel candidate drug targets for systemic scleroderma were identified using RNAi in phenotypic assays in scleroderma patient-derived fibroblasts…

This poster outlines a study to identify and validate novel candidate drug targets using RNAi in phenotypic assays in systemic sclerosis patient-derived fibroblasts.

A high throughput primary screen measuring the reversion of myofibroblasts was developed to screen Charles River’s SilenceSelect® adenoviral shRNA library (~21,000 shRNAs screened). Inhibition of aSMA mRNA expression was measured via fluorescence in situ hybridization (FISH), and ~550 shRNAs were selected for rescreen. Follow on 2D and 3D validation assays including gel contractility, impedance and skin equivalent (SE) are described.

This poster note is restricted - login or subscribe free to access

DTR Issue 3 2021 MiniMagThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here